OCUL Sales Drop 18%
Ocular Therapeutix (NASDAQ:OCUL), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant widening in net loss due to increased research and marketing investments. Commercial revenue from its only marketed product, DEXTENZA, fell year over year. Revenue (GAAP) was $13.5 million, slightly above expectations of $13.46 million. However, the reported net loss per share of $(0.39) (GAAP) missed analyst estimates by 8.4%. The quarter reflects continued clinical advancement in key programs but highlights persistent reimbursement challenges and a rising cash burn rate.
Source: Analyst estimates for the quarter provided by FactSet.
Ocular Therapeutix (NASDAQ:OCUL) is focused on developing innovative drug delivery solutions for eye diseases using its proprietary ELUTYX hydrogel technology. Its lead product DEXTENZA is an FDA-approved ocular implant used after eye surgery to control inflammation and pain. It also has a pipeline of drug candidates targeting retinal diseases, including wet age-related macular degeneration (AMD) and diabetic eye diseases.
Source Fool.com
Ocular Therapeutix Inc. Aktie
Die Community bevorzugt Ocular Therapeutix Inc., mit deutlich mehr Buy- (23) als Sell-Einschätzungen (2).
Die Community prognostiziert für Ocular Therapeutix Inc. ein Kursziel von 17 €, was eine Steigerung von mehr als 100% gegenüber dem aktuellen Kurs von 6.64 € bedeutet.
